Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700027165

Next Previous
X
Search
Trial Profile

Clinical Trials Insight: 700027165

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2008

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sparsentan (Primary)
  • Indications Diabetic nephropathies; Hypertension
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Pharmacopeia

    • Most Recent Events

    • 15 Apr 2008 Interim results will be reported at ASH 2008 (abstract P-14).
    • 04 Dec 2007 Additional positive safety results reported in a Pharmacopeia media release.
    • 29 Sep 2007 Early results have indicated no safety or tolerability issues. As a result, the study will be expanded to include a 1000mg dose. The Company expects to report findings from this dose later in 2007.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top